Ricciuti B - Search Results

1

Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.

Lamberti G, Andrini E, Sisi M, Federico AD, Ricciuti B. Lamberti G, et al. Among authors: ricciuti b. Future Oncol. 2020 Aug;16(23):1751-1766. doi: 10.2217/fon-2020-0215. Epub 2020 Jun 15. Future Oncol. 2020. PMID: 32539551 Review.

2

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence.

Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R, Pirro M. Ricciuti B, et al. Pharmacol Ther. 2019 Apr;196:105-116. doi: 10.1016/j.pharmthera.2018.12.004. Epub 2018 Dec 4. Pharmacol Ther. 2019. PMID: 30521884 Review.

3

ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F. Chiari R, et al. Among authors: ricciuti b. Clin Lung Cancer. 2020 Jan;21(1):15-20. doi: 10.1016/j.cllc.2019.06.012. Epub 2019 Jun 18. Clin Lung Cancer. 2020. PMID: 31607443 Clinical Trial.

4

Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer.

Lamberti G, Andrini E, Ricciuti B. Lamberti G, et al. Among authors: ricciuti b. J Thorac Dis. 2019 Sep;11(Suppl 15):S1831-S1834. doi: 10.21037/jtd.2019.08.104. J Thorac Dis. 2019. PMID: 31632761 Free PMC article. No abstract available.

5

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.

Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Abu-Sbeih H, et al. Among authors: ricciuti b. J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4. J Clin Oncol. 2020. PMID: 31800340 Free PMC article.

6

Antibody-drug conjugates for lung cancer in the era of personalized oncology.

Ricciuti B, Lamberti G, Andrini E, Genova C, De Giglio A, Bianconi V, Sahebkar A, Chiari R, Pirro M. Ricciuti B, et al. Semin Cancer Biol. 2021 Feb;69:268-278. doi: 10.1016/j.semcancer.2019.12.024. Epub 2019 Dec 30. Semin Cancer Biol. 2021. PMID: 31899248 Review.

7

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.

Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM. Recondo G, et al. Among authors: ricciuti b. Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034073

8

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

Ricciuti B, Lamberti G, Roila F, Metro G. Ricciuti B, et al. Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S378-S382. doi: 10.21037/tlcr.2019.04.15. Transl Lung Cancer Res. 2019. PMID: 32038919 Free PMC article. No abstract available.

9

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.

Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Lamberti G, et al. Among authors: ricciuti b. Ann Oncol. 2020 Jun;31(6):807-814. doi: 10.1016/j.annonc.2020.02.017. Epub 2020 Apr 27. Ann Oncol. 2020. PMID: 32171752 Free article.

10

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.

Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Ricciuti B, et al. Clin Cancer Res. 2020 Aug 1;26(15):4135-4142. doi: 10.1158/1078-0432.CCR-19-3529. Epub 2020 Apr 24. Clin Cancer Res. 2020. PMID: 32332016

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters